Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference63 articles.
1. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.;Atkins;J Clin Oncol,2008
2. Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial.;Margolin;J Cancer Res Clin Oncol,1999
3. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.;McDermott;Clin Cancer Res,2000
4. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.;Chapman;N Engl J Med,2011
5. Improved survival with MEK inhibition in BRAF-mutated melanoma.;Flaherty;N Engl J Med,2012
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献